MedTrace Logo

the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia

NCT05864170 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2024-11-29

No results posted yet for this study

Summary

This is an open label study to evaluate the safety and efficacy of β-globin Restored Autologous Hematopoietic Stem Cells in ß-Thalassemia Major Patients

Conditions

  • β-thalassemia

Interventions

BIOLOGICAL

β-globin restored autologous hematopoietic stem cells

β-globin-restored autologous hematopoietic stem cells modified with LentiHBBT87Q

Sponsors & Collaborators

  • Shenzhen Hemogen

    lead INDUSTRY

Principal Investigators

  • Chao Liu, PHD · Shenzhen Hemogen

  • Li Yu · Shenzhen University General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-27
Primary Completion
2025-12-30
Completion
2025-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05864170 on ClinicalTrials.gov